Pulmonary Fibrosis News and Research

RSS

Small numbers of ANA- and RP-negative patients with systemic sclerosis

There exists a very small subgroup of patients with systemic sclerosis who lack circulating antinuclear antibodies and who do not have Raynaud's phenomenon, research shows.

31 Dec 2012

First U.S. breathing lung transplant performed in Ronald Reagan UCLA Medical Center

First there was the "heart in a box," a revolutionary experimental technology that allows donor hearts to be delivered to transplant recipients warm and beating rather than frozen in an ice cooler. Now that same technology is being used to deliver "breathing lungs."

27 Nov 2012

Scientists uncover new role for TLR4 in development of tissue fibrosis or scarring

An international multi-disciplinary research team led by Northwestern Medicine scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.

21 Nov 2012

SCCA to raise awareness about importance of lung cancer screening

Lung cancer is the No. 1 cause of cancer deaths in the United States, despite the fact it is largely preventable. For people at high risk of developing lung cancer, such as current or former longtime smokers, screening for the disease with low-dose CT scans is now a viable option that has been shown to significantly reduce mortality rates. In conjunction with National Lung Cancer Awareness Month, Seattle Cancer Care Alliance (SCCA) wants to raise awareness about the importance of prevention and early detection for at-risk populations.

9 Nov 2012

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Chinese herbs, including JHQG, BFXL, and BFHX, may show significant benefits for patients with non-small cell lung cancer (NSCLC), idiopathic pulmonary fibrosis (IPF), and influenza.

22 Oct 2012

New nanodevice lays foundations for future development of novel therapies against aging

A team of Spanish scientists has developed an intelligent nanodevice that lays the foundations for the future development of new therapies against aging. The device consists of nanoparticles that can selectively release drugs in aged human cells.

4 Oct 2012

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

InterMune, Inc. today announced that Health Canada has approved Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adult patients.

3 Oct 2012

Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

The Coalition for Pulmonary Fibrosis (CPF) proudly announces the winners of its three annual awards for distinguished service. Each honoree has made vital contributions to the effort to fight Pulmonary Fibrosis (PF) – in research, humanitarian and advocacy efforts.

28 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma

There are many different chronic respiratory diseases. Verona Pharma is mainly focused on two diseases: asthma and COPD. Asthma is a very common disease and unfortunately it has been increasing in prevalence in developed countries. This is the same with COPD; however, there may be different reasons for this.

25 Sep 2012

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF).

24 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Each year around the world, as many as 48,000 people are diagnosed with pulmonary fibrosis and 40,000 people die – the same number of people who are lost to breast cancer annually. Pulmonary fibrosis is a devastating disease that robs people of their ability to breathe. To help raise awareness about this unknown deadly disease, the Coalition for Pulmonary Fibrosis (CPF) is kicking off "Pulmonary Fibrosis Awareness Month" this September.

10 Sep 2012

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

InterMune, Inc. announced that new analyses of data from the RECAP extension study of Esbriet (pirfenidone) were presented today at the 2012 Annual Congress of the European Respiratory Society (ERS) in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

3 Sep 2012

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

Boehringer Ingelheim presented today for the first time data from a Phase II dose ranging study investigationg the combination of olodaterol, an investigational long-acting beta2-agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA), in COPD patients, compared to the investigational agent olodaterol alone.

3 Sep 2012

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

Boehringer Ingelheim presented today the first data from the Phase III UniTinA-asthma program. In two studies, presented at the 2012 European Respiratory Society (ERS) Congress in Vienna, Austria, tiotropium delivered once daily via the Respimat inhaler significantly improved lung function and reduced asthma exacerbations in patients who remained symptomatic on current treatment with at least high dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).

3 Sep 2012

MedQIA develops new software that forms the basis of Imaging Biomarker Information System

MedQIA has developed a software toolkit of image analysis routines that forms the basis of an Imaging Biomarker Information System (IBIS).

27 Aug 2012

Researchers identify how telomerase is recruited to chromosome ends

Stem cells are special. Nestled in muscle and skin, organ and bone, they bide their time over years or decades until called to replace damaged or lost tissue. One secret to their longevity is an enzyme called telomerase, which stills the relentless ticking of the molecular clock that limits the life span of other cells.

3 Aug 2012

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen, Inc., today announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

31 Jul 2012

Psoriasis link with autoimmune diseases underscored

Patients with psoriasis are nearly twice as likely to have an autoimmune disease as individuals without the condition, suggest study findings.

8 Jun 2012

Pulmonary Fibrosis News and Research

Small numbers of ANA- and RP-negative patients with systemic sclerosis

First U.S. breathing lung transplant performed in Ronald Reagan UCLA Medical Center

Scientists uncover new role for TLR4 in development of tissue fibrosis or scarring

SCCA to raise awareness about importance of lung cancer screening

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

New nanodevice lays foundations for future development of novel therapies against aging

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

MedQIA develops new software that forms the basis of Imaging Biomarker Information System

Researchers identify how telomerase is recruited to chromosome ends

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

Psoriasis link with autoimmune diseases underscored

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News